ifosfamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives 1421 3778-73-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ifosfamide
  • holoxan
  • ifomide
  • ifosfamid
  • ifosfomide
  • ifosphamide
  • iphosphamide
  • isoendoxan
  • isofosfamide
  • isophosphamide
  • mitoxana
  • naxamide
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
  • Molecular weight: 261.08
  • Formula: C7H15Cl2N2O2P
  • CLOGP: 0.92
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 41.57
  • ALOGS: -1.24
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 100 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 113.59 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 92 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.62 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.483 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.277 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 65.917 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.780 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 91.230 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 88.800 % High 1
herg hERG pIC50 3.476 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.683 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.565 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 91.390 % High 1
kinase-safety-class CDK5,EIF2AK3,GRK2,PDK1,PDK2,PDK4 6
kinase-selectivity-class AXL,BRAF,CDK4,CHUK,GRK2,MAP2K6,TEK 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.743 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.929 High 1
mppb Mouse plasma protein binding (% unbound) 94.460 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.486 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 90.420 % High 1
rh-clint Rat hepatocyte intrinsic clearance 5.741 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 97.310 % High 1
rppb Rat plasma protein binding (% unbound) 93.400 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 887.156 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1676.25 29.03 802 21486 157547 90448612
Disease progression 1051.80 29.03 585 21703 156030 90450129
Encephalopathy 934.67 29.03 371 21917 46073 90560086
Neutropenia 832.75 29.03 575 21713 224329 90381830
Myelodysplastic syndrome 623.92 29.03 223 22065 20680 90585479
Mucosal inflammation 604.33 29.03 291 21997 57334 90548825
Off label use 541.12 29.03 964 21324 1101288 89504871
Acute myeloid leukaemia 493.25 29.03 187 22101 20453 90585706
Pancytopenia 456.83 29.03 313 21975 119950 90486209
Myelosuppression 436.18 29.03 228 22060 53363 90552796
Bone marrow failure 435.11 29.03 194 22094 32027 90574132
Thrombocytopenia 428.45 29.03 377 21911 208348 90397811
Ovarian failure 424.31 29.03 95 22193 1548 90604611
Haematotoxicity 297.33 29.03 113 22175 12422 90593737
Neurotoxicity 279.34 29.03 126 22162 21341 90584818
Malignant neoplasm progression 257.65 29.03 212 22076 106658 90499501
Anaemia 220.89 29.03 346 21942 352456 90253703
Product use in unapproved indication 219.22 29.03 336 21952 335900 90270259
Second primary malignancy 208.69 29.03 83 22205 10295 90595864
Febrile bone marrow aplasia 199.72 29.03 79 22209 9659 90596500
Cytopenia 194.47 29.03 92 22196 17357 90588802
Diffuse large B-cell lymphoma recurrent 190.93 29.03 59 22229 3467 90602692
Cytokine release syndrome 180.12 29.03 102 22186 27871 90578288
Cardiotoxicity 174.49 29.03 75 22213 11314 90594845
Toxic encephalopathy 166.00 29.03 67 22221 8632 90597527
Fanconi syndrome 155.52 29.03 44 22244 1899 90604260
Neoplasm progression 155.04 29.03 110 22178 44376 90561783
Therapy partial responder 151.77 29.03 84 22204 21959 90584200
Cystitis haemorrhagic 150.08 29.03 55 22233 5458 90600701
Leukopenia 148.91 29.03 152 22136 100558 90505601
Aplasia 135.86 29.03 47 22241 3944 90602215
Arthralgia 131.58 29.03 18 22270 778504 89827655
Neutropenic sepsis 127.31 29.03 70 22218 18060 90588099
Oligohydramnios 118.85 29.03 50 22238 7151 90599008
Posterior reversible encephalopathy syndrome 113.73 29.03 70 22218 22269 90583890
Pain 107.18 29.03 56 22232 996285 89609874
Renal tubular disorder 106.21 29.03 37 22251 3170 90602989
Septic shock 104.84 29.03 116 22172 84044 90522115
Disease recurrence 104.05 29.03 81 22207 37572 90568587
Malignant transformation 98.28 29.03 24 22264 578 90605581
Diffuse large B-cell lymphoma refractory 96.95 29.03 30 22258 1770 90604389
Gene mutation 96.04 29.03 31 22257 2099 90604060
Fatigue 90.14 29.03 91 22197 1153932 89452227
Abdominal discomfort 88.17 29.03 8 22280 477320 90128839
Premature menopause 88.13 29.03 26 22262 1303 90604856
Rash 85.13 29.03 45 22243 796055 89810104
Weight increased 82.88 29.03 5 22283 417922 90188237
Immune effector cell-associated neurotoxicity syndrome 81.87 29.03 36 22252 5732 90600427
Leukoerythroblastosis 80.44 29.03 18 22270 292 90605867
Nasopharyngitis 80.34 29.03 5 22283 407099 90199060
Pruritus 79.45 29.03 18 22270 541507 90064652
Polyneuropathy 77.18 29.03 52 22236 19289 90586870
Metastases to lymph nodes 76.24 29.03 43 22245 11646 90594513
Foetal growth restriction 73.62 29.03 39 22249 9341 90596818
Swelling 72.31 29.03 9 22279 419049 90187110
Ascites 72.23 29.03 73 22215 47667 90558492
Peripheral swelling 70.97 29.03 9 22279 413097 90193062
Drug hypersensitivity 70.88 29.03 14 22274 463595 90142564
Systemic lupus erythematosus 69.76 29.03 5 22283 361891 90244268
Headache 69.58 29.03 66 22222 862680 89743479
Hypersensitivity 68.94 29.03 14 22274 454663 90151496
Sepsis 68.10 29.03 142 22146 179672 90426487
Infusion related reaction 67.14 29.03 11 22277 416769 90189390
Platelet count decreased 66.31 29.03 120 22168 136849 90469310
Metastases to peritoneum 65.74 29.03 28 22260 4127 90602032
Drug ineffective 64.90 29.03 569 21719 1383729 89222430
Nephrogenic diabetes insipidus 64.42 29.03 19 22269 951 90605208
Insomnia 63.16 29.03 5 22283 333469 90272690
Fall 63.13 29.03 20 22268 481790 90124369
Contraindicated product administered 62.94 29.03 4 22284 320135 90286024
Malaise 62.74 29.03 33 22255 585953 90020206
Nephropathy toxic 62.65 29.03 39 22249 12649 90593510
Myeloid leukaemia 61.43 29.03 16 22272 503 90605656
Sinusitis 60.08 29.03 7 22281 343081 90263078
Neoplasm recurrence 58.40 29.03 24 22264 3235 90602924
Arthropathy 58.23 29.03 10 22278 366232 90239927
Neutrophil count decreased 57.34 29.03 79 22209 71453 90534706
Ovarian disorder 56.90 29.03 17 22271 890 90605269
Pain in extremity 56.74 29.03 20 22268 450509 90155650
T-cell lymphoma refractory 53.81 29.03 10 22278 59 90606100
Acute kidney injury 53.68 29.03 187 22101 320200 90285959
Urticaria 53.24 29.03 7 22281 312727 90293432
Leukoencephalopathy 52.16 29.03 25 22263 4848 90601311
Lymphoma 50.57 29.03 35 22253 13556 90592603
Dizziness 49.91 29.03 43 22245 589241 90016918
Metastases to lung 49.90 29.03 37 22251 15954 90590205
Contusion 49.78 29.03 3 22285 251213 90354946
Oesophageal candidiasis 49.68 29.03 27 22261 6802 90599357
Tumour lysis syndrome 49.38 29.03 32 22256 11120 90595039
Salivary gland cancer 48.51 29.03 11 22277 190 90605969
Pneumothorax 48.15 29.03 39 22249 19128 90587031
Lymphopenia 48.08 29.03 42 22246 22839 90583320
Asthma 47.66 29.03 3 22285 242157 90364002
Hepatic enzyme increased 47.18 29.03 15 22273 360721 90245438
Dyspnoea 47.07 29.03 91 22197 880864 89725295
Discomfort 47.03 29.03 6 22282 274329 90331830
Multiple organ dysfunction syndrome 46.74 29.03 70 22218 68266 90537893
Deafness 46.65 29.03 41 22247 22473 90583686
Impaired healing 45.80 29.03 3 22285 234196 90371963
Hypoaesthesia 44.93 29.03 11 22277 314199 90291960
Abdominal pain upper 43.20 29.03 14 22274 332660 90273499
Vena cava thrombosis 43.05 29.03 18 22270 2534 90603625
Haemophagocytic lymphohistiocytosis 42.14 29.03 33 22255 15426 90590733
Blood stem cell transplant failure 42.03 29.03 10 22278 215 90605944
Hypertension 41.71 29.03 31 22257 457501 90148658
Metastases to breast 41.01 29.03 11 22277 388 90605771
Pyrexia 40.89 29.03 290 21998 660195 89945964
Cough 40.61 29.03 20 22268 368942 90237217
Duodenal ulcer perforation 40.04 29.03 4 22284 221284 90384875
Escherichia bacteraemia 39.86 29.03 22 22266 5713 90600446
Blood lactate dehydrogenase increased 39.85 29.03 40 22248 25892 90580267
White blood cell count abnormal 39.43 29.03 24 22264 7480 90598679
Rhabdomyosarcoma recurrent 38.81 29.03 7 22281 34 90606125
Amenorrhoea 38.55 29.03 28 22260 11694 90594465
White blood cell count decreased 38.52 29.03 109 22179 167000 90439159
Gastritis haemorrhagic 38.29 29.03 15 22273 1785 90604374
Postictal state 38.29 29.03 14 22274 1379 90604780
Dysplasia 38.28 29.03 14 22274 1380 90604779
Periorbital cellulitis 37.87 29.03 12 22276 765 90605394
Muscle spasms 37.64 29.03 8 22280 251875 90354284
Foetal death 37.56 29.03 35 22253 20688 90585471
COVID-19 pneumonia 37.46 29.03 33 22255 18144 90588015
Dyspepsia 37.42 29.03 3 22285 198157 90408002
Strongyloidiasis 36.39 29.03 14 22274 1588 90604571
Vulvovaginitis 36.27 29.03 10 22278 392 90605767
Neuropathy peripheral 35.21 29.03 93 22195 136877 90469282
Subdural hygroma 34.99 29.03 9 22279 269 90605890
Klebsiella sepsis 34.95 29.03 14 22274 1767 90604392
Myelopathy 34.84 29.03 17 22271 3427 90602732
Congestive cardiomyopathy 34.79 29.03 22 22266 7332 90598827
Drug resistance 34.53 29.03 40 22248 30409 90575750
Blister 34.41 29.03 10 22278 254988 90351171
Systemic candida 34.40 29.03 19 22269 4940 90601219
Folliculitis 33.76 29.03 5 22283 204348 90401811
Premature baby 33.70 29.03 36 22252 25041 90581118
Metastases to meninges 33.53 29.03 17 22271 3718 90602441
Renal impairment 32.80 29.03 77 22211 105344 90500815
Hypophosphataemia 32.69 29.03 28 22260 14826 90591333
Peripheral sensory neuropathy 32.50 29.03 23 22265 9227 90596932
Fanconi syndrome acquired 32.06 29.03 12 22276 1262 90604897
Clostridium difficile infection 32.04 29.03 42 22246 36203 90569956
Cytomegalovirus infection 31.95 29.03 36 22252 26566 90579593
Amniotic fluid index decreased 31.92 29.03 6 22282 38 90606121
Quadriplegia 31.90 29.03 14 22274 2217 90603942
Drug ineffective for unapproved indication 31.73 29.03 58 22230 66586 90539573
Metastases to liver 31.27 29.03 37 22251 28770 90577389
Hypoalbuminaemia 31.05 29.03 28 22260 15869 90590290
Enterococcal infection 30.91 29.03 23 22265 9968 90596191
Delayed puberty 30.81 29.03 7 22281 122 90606037
Gastrooesophageal reflux disease 30.10 29.03 3 22285 166334 90439825
Drug intolerance 29.69 29.03 40 22248 447551 90158608
Condition aggravated 29.63 29.03 64 22224 595481 90010678

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1468.42 21.39 1146 29491 184557 42406141
Disease progression 1133.96 21.39 887 29750 142769 42447929
Neutropenia 512.60 21.39 671 29966 198760 42391938
Off label use 498.02 21.39 1275 29362 637060 41953638
Encephalopathy 452.68 21.39 312 30325 41021 42549677
Myelodysplastic syndrome 400.50 21.39 232 30405 22513 42568185
Myelosuppression 395.61 21.39 285 30352 40176 42550522
Acute myeloid leukaemia 349.87 21.39 211 30426 22045 42568653
Diffuse large B-cell lymphoma recurrent 343.24 21.39 130 30507 4756 42585942
Thrombocytopenia 329.96 21.39 532 30105 189747 42400951
Bone marrow failure 311.79 21.39 228 30409 32865 42557833
Haematotoxicity 296.92 21.39 149 30488 10836 42579862
Mucosal inflammation 274.29 21.39 250 30387 49124 42541574
Diffuse large B-cell lymphoma refractory 251.25 21.39 82 30555 1915 42588783
Malignant neoplasm progression 245.91 21.39 344 30293 108056 42482642
Neoplasm progression 235.81 21.39 183 30454 28817 42561881
Pancytopenia 235.51 21.39 352 30285 117391 42473307
Second primary malignancy 221.56 21.39 117 30520 9458 42581240
Therapy partial responder 186.35 21.39 137 30500 19884 42570814
Product use in unapproved indication 173.23 21.39 398 30239 184058 42406640
Blood lactate dehydrogenase increased 164.51 21.39 142 30495 25939 42564759
Fanconi syndrome 160.30 21.39 57 30580 1737 42588961
Cytopenia 156.70 21.39 117 30520 17380 42573318
Neurotoxicity 141.57 21.39 125 30512 23526 42567172
Renal tubular disorder 130.89 21.39 66 30571 4843 42585855
Disease recurrence 126.47 21.39 130 30507 29548 42561150
Fall 120.13 21.39 14 30623 234506 42356192
Neutropenic sepsis 119.61 21.39 96 30541 15850 42574848
Tumour lysis syndrome 116.40 21.39 109 30528 22122 42568576
Febrile bone marrow aplasia 116.35 21.39 79 30558 10102 42580596
Sepsis 115.71 21.39 360 30277 198974 42391724
Toxic encephalopathy 114.58 21.39 68 30569 6885 42583813
Cytokine release syndrome 112.39 21.39 149 30488 44378 42546320
Osteosarcoma 102.08 21.39 27 30610 291 42590407
Nephropathy toxic 100.77 21.39 89 30548 16749 42573949
Leukopenia 100.24 21.39 187 30450 74559 42516139
Product dose omission issue 97.32 21.39 3 30634 154362 42436336
Neoplasm recurrence 94.93 21.39 44 30593 2680 42588018
Drug ineffective 94.24 21.39 772 29865 629425 41961273
Metastases to lung 92.60 21.39 72 30565 11352 42579346
Salivary gland cancer 91.32 21.39 25 30612 310 42590388
Cardiotoxicity 85.61 21.39 58 30579 7387 42583311
Malignant transformation 83.33 21.39 30 30607 948 42589750
Aplasia 81.46 21.39 48 30589 4795 42585903
Stomatitis 79.11 21.39 135 30502 50194 42540504
Anal inflammation 77.66 21.39 36 30601 2193 42588505
Fatigue 74.86 21.39 124 30513 435517 42155181
Cystitis haemorrhagic 74.66 21.39 53 30584 7276 42583422
Blood stem cell transplant failure 74.28 21.39 23 30614 450 42590248
Dyspnoea 73.30 21.39 129 30508 442492 42148206
Pyrexia 72.84 21.39 508 30129 393534 42197164
Rash 72.39 21.39 56 30581 276898 42313800
Dizziness 72.29 21.39 45 30592 249209 42341489
Therapy non-responder 72.13 21.39 134 30503 53225 42537473
B-cell lymphoma recurrent 71.79 21.39 26 30611 836 42589862
Fanconi syndrome acquired 70.78 21.39 33 30604 2037 42588661
SARS-CoV-2 test negative 69.19 21.39 31 30606 1744 42588954
Anaemia 67.01 21.39 386 30251 279892 42310806
Insomnia 65.94 21.39 5 30632 118248 42472450
Myocardial infarction 64.44 21.39 7 30630 124002 42466696
Hypogammaglobulinaemia 59.74 21.39 57 30580 11834 42578864
Transformation to acute myeloid leukaemia 58.60 21.39 24 30613 1081 42589617
Septic shock 58.14 21.39 171 30466 91501 42499197
Venoocclusive liver disease 56.79 21.39 52 30585 10250 42580448
Inappropriate schedule of product administration 56.60 21.39 3 30634 95899 42494799
Azoospermia 55.53 21.39 19 30618 515 42590183
Rhabdomyosarcoma recurrent 54.62 21.39 14 30623 132 42590566
Myalgia 53.74 21.39 4 30633 96076 42494622
Arthralgia 52.94 21.39 42 30595 205196 42385502
Lymphadenopathy 50.45 21.39 88 30549 33277 42557421
Blood pressure increased 49.90 21.39 7 30630 101921 42488777
Proctalgia 49.59 21.39 41 30596 7052 42583646
Metastases to spleen 48.63 21.39 17 30620 492 42590206
Nervous system disorder 47.19 21.39 60 30577 17135 42573563
Metastases to muscle 47.11 21.39 14 30623 237 42590461
Diffuse large B-cell lymphoma 46.89 21.39 45 30592 9409 42581289
Encephalitis enteroviral 45.97 21.39 13 30624 183 42590515
Nasopharyngitis 45.57 21.39 4 30633 83992 42506706
Immune effector cell-associated neurotoxicity syndrome 44.98 21.39 44 30593 9417 42581281
Vena cava thrombosis 44.60 21.39 22 30615 1539 42589159
Cardiac failure congestive 44.03 21.39 5 30632 85597 42505101
Headache 43.98 21.39 65 30572 239304 42351394
Bradycardia 43.96 21.39 5 30632 85479 42505219
Delayed puberty 43.85 21.39 13 30624 218 42590480
Ganglioneuroblastoma 43.69 21.39 9 30628 27 42590671
Weight increased 43.29 21.39 12 30625 107971 42482727
Body height below normal 43.26 21.39 13 30624 229 42590469
Treatment failure 42.77 21.39 120 30517 62504 42528194
Acute lymphocytic leukaemia 42.50 21.39 28 30609 3403 42587295
Peripheral swelling 42.36 21.39 7 30630 90263 42500435
Accident 42.18 21.39 36 30601 6467 42584231
Overdose 41.64 21.39 12 30625 105252 42485446
Cellulitis gangrenous 41.34 21.39 13 30624 268 42590430
Tubulointerstitial nephritis 41.08 21.39 78 30559 31470 42559228
Chromosome analysis abnormal 40.78 21.39 12 30625 196 42590502
Depression 40 21.39 15 30622 111348 42479350
Anxiety 39.31 21.39 18 30619 118542 42472156
Drug ineffective for unapproved indication 39.23 21.39 96 30541 46067 42544631
Hyperkalaemia 38.28 21.39 6 30631 80452 42510246
Ameloblastoma 38.21 21.39 10 30627 103 42590595
Pruritus 37.94 21.39 48 30589 188723 42401975
Metastases to retroperitoneum 37.60 21.39 12 30625 260 42590438
Muscle spasms 37.54 21.39 8 30629 86036 42504662
Hepatitis B reactivation 37.41 21.39 29 30608 4549 42586149
Hospitalisation 36.62 21.39 5 30632 74325 42516373
Gastrointestinal toxicity 36.48 21.39 27 30610 3952 42586746
Post-acute COVID-19 syndrome 35.66 21.39 13 30624 426 42590272
Abdominal discomfort 34.94 21.39 6 30631 75249 42515449
Recurrent cancer 34.65 21.39 19 30618 1654 42589044
Parasitic gastroenteritis 34.59 21.39 10 30627 153 42590545
Chest pain 34.17 21.39 30 30607 139500 42451198
Bacteraemia 33.96 21.39 63 30574 24977 42565721
Rickets 33.83 21.39 8 30629 52 42590646
Asthenia 33.21 21.39 98 30539 280695 42310003
Neuroblastoma recurrent 32.72 21.39 12 30625 400 42590298
Infection 31.84 21.39 162 30475 111906 42478792
BK virus infection 31.27 21.39 35 30602 8749 42581949
Hyperhidrosis 31.17 21.39 13 30624 90499 42500199
Basal cell naevus syndrome 31.15 21.39 7 30630 35 42590663
Cough 31.11 21.39 50 30587 178053 42412645
Condition aggravated 30.83 21.39 91 30546 260663 42330035
Musculoskeletal stiffness 30.66 21.39 3 30634 57762 42532936
Autoimmune neutropenia 30.57 21.39 11 30626 347 42590351
Haematopoietic stem cell mobilisation 30.45 21.39 11 30626 351 42590347
Lymphoma 30.23 21.39 44 30593 14277 42576421
Meningitis tuberculous 30.16 21.39 13 30624 666 42590032
Drug hypersensitivity 30.09 21.39 17 30620 99372 42491326
Device related infection 30.02 21.39 53 30584 20226 42570472
Adenovirus reactivation 29.51 21.39 11 30626 384 42590314
Adenoviral hepatitis 29.16 21.39 12 30625 547 42590151
Lymphopenia 28.92 21.39 54 30583 21509 42569189
Ototoxicity 28.86 21.39 19 30618 2306 42588392
Norovirus infection 28.64 21.39 13 30624 754 42589944
Renal tubular injury 28.27 21.39 17 30620 1762 42588936
Urticaria 28.26 21.39 9 30628 74027 42516671
Abdominal pain upper 28.23 21.39 12 30625 82597 42508101
Osteosarcoma recurrent 28.00 21.39 8 30629 117 42590581
Vision blurred 27.96 21.39 3 30634 53696 42537002
Candida infection 27.60 21.39 53 30584 21557 42569141
Incorrect dose administered 27.48 21.39 3 30634 52971 42537727
Pleuroparenchymal fibroelastosis 26.41 21.39 8 30629 145 42590553
Lymphoma transformation 26.34 21.39 11 30626 521 42590177
Peripheral blood stem cell apheresis 26.25 21.39 8 30629 148 42590550
White blood cell count decreased 26.23 21.39 152 30485 110244 42480454
Ill-defined disorder 25.96 21.39 44 30593 16252 42574446
Metastases to bone marrow 25.94 21.39 11 30626 541 42590157
General physical health deterioration 25.90 21.39 43 30594 151203 42439495
Staphylococcal infection 25.56 21.39 72 30565 37571 42553127
Diabetes mellitus 25.37 21.39 6 30631 60081 42530617
Platelet count abnormal 25.31 21.39 21 30616 3628 42587070
Rectal haemorrhage 25.25 21.39 3 30634 49603 42541095
Vomiting 25.06 21.39 318 30319 289405 42301293
Platelet count decreased 25.04 21.39 178 30459 138403 42452295
Oedema peripheral 24.91 21.39 37 30600 136039 42454659
Cerebrovascular accident 24.87 21.39 20 30617 97140 42493558
Tremor 24.75 21.39 20 30617 96909 42493789
Pain in extremity 24.71 21.39 44 30593 150560 42440138
Haematochezia 24.35 21.39 6 30631 58430 42532268
Hypotension 23.69 21.39 100 30537 257531 42333167
Bronchitis 23.67 21.39 3 30634 47198 42543500
Pseudomonal bacteraemia 23.65 21.39 17 30620 2379 42588319
Synovial sarcoma metastatic 23.58 21.39 5 30632 18 42590680
Neutropenic colitis 23.54 21.39 22 30615 4448 42586250
Clostridium difficile infection 23.52 21.39 51 30586 22608 42568090
Coronary artery disease 23.41 21.39 5 30632 53715 42536983
Clostridium difficile colitis 23.41 21.39 49 30588 21203 42569495
B-cell lymphoma refractory 23.37 21.39 8 30629 217 42590481
Ejection fraction decreased 23.26 21.39 50 30587 22037 42568661
Agranulocytosis 23.23 21.39 61 30576 30551 42560147
Pain 23.16 21.39 94 30543 244754 42345944
Death 23.14 21.39 222 30415 470963 42119735
Human herpesvirus 8 infection 23.00 21.39 14 30623 1483 42589215
Aspergillus infection 22.93 21.39 41 30596 15796 42574902
Gait disturbance 22.88 21.39 22 30615 97978 42492720
Drug resistance 22.75 21.39 65 30572 34183 42556515
Bone sarcoma 22.74 21.39 6 30631 64 42590634
Escherichia bacteraemia 22.73 21.39 23 30614 5126 42585572
Atrial fibrillation 22.70 21.39 41 30596 139552 42451146
Pneumonia adenoviral 22.44 21.39 9 30628 384 42590314
Posterior reversible encephalopathy syndrome 22.28 21.39 36 30601 12785 42577913
Hypertension 22.26 21.39 55 30582 167149 42423549
Central nervous system necrosis 21.98 21.39 8 30629 261 42590437
Neutrophil count decreased 21.88 21.39 97 30540 63318 42527380
Blastic plasmacytoid dendritic cell neoplasia 21.80 21.39 6 30631 76 42590622
Salivary gland neoplasm 21.78 21.39 5 30632 28 42590670
Hepatitis E 21.67 21.39 18 30619 3116 42587582

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 2974.62 21.89 1793 46305 314974 110226227
Disease progression 1595.76 21.89 1103 46995 242931 110298270
Encephalopathy 1251.47 21.89 639 47459 80416 110460785
Neutropenia 1250.78 21.89 1140 46958 373480 110167721
Off label use 913.22 21.89 2001 46097 1498184 109043017
Myelodysplastic syndrome 843.72 21.89 383 47715 37101 110504100
Mucosal inflammation 757.42 21.89 489 47609 95652 110445549
Acute myeloid leukaemia 741.37 21.89 352 47746 37758 110503443
Myelosuppression 741.12 21.89 479 47619 93861 110447340
Thrombocytopenia 735.24 21.89 829 47269 348056 110193145
Bone marrow failure 713.76 21.89 393 47705 57455 110483746
Pancytopenia 645.37 21.89 611 47487 209002 110332199
Haematotoxicity 543.49 21.89 237 47861 20845 110520356
Malignant neoplasm progression 539.28 21.89 510 47588 174057 110367144
Diffuse large B-cell lymphoma recurrent 413.67 21.89 140 47958 6159 110535042
Neurotoxicity 365.23 21.89 228 47870 41979 110499222
Second primary malignancy 357.68 21.89 169 47929 17899 110523302
Neoplasm progression 347.19 21.89 260 47838 64335 110476866
Cytokine release syndrome 334.09 21.89 263 47835 70043 110471158
Product use in unapproved indication 331.96 21.89 651 47447 446726 110094475
Fanconi syndrome 327.97 21.89 102 47996 3417 110537784
Febrile bone marrow aplasia 290.41 21.89 145 47953 17320 110523881
Therapy partial responder 290.24 21.89 188 47910 36873 110504328
Cytopenia 284.27 21.89 172 47926 29944 110511257
Anaemia 269.81 21.89 676 47422 546410 109994791
Leukopenia 252.07 21.89 317 47781 148474 110392727
Toxic encephalopathy 249.10 21.89 125 47973 15089 110526112
Cardiotoxicity 245.37 21.89 128 47970 16753 110524448
Renal tubular disorder 236.31 21.89 97 48001 7332 110533869
Sepsis 213.54 21.89 452 47646 326894 110214307
Disease recurrence 211.45 21.89 190 47908 60594 110480607
Cystitis haemorrhagic 198.96 21.89 100 47998 12109 110529092
Aplasia 197.95 21.89 87 48011 7786 110533415
Arthralgia 196.17 21.89 49 48049 779583 109761618
Neutropenic sepsis 195.30 21.89 137 47961 30609 110510592
Drug ineffective 186.13 21.89 1211 46887 1519329 109021872
Tumour lysis syndrome 185.83 21.89 133 47965 30668 110510533
Diffuse large B-cell lymphoma refractory 181.27 21.89 60 48038 2461 110538740
Joint swelling 177.49 21.89 3 48095 442842 110098359
Fall 172.38 21.89 28 48070 603454 109937747
Malignant transformation 166.82 21.89 50 48048 1475 110539726
Septic shock 165.10 21.89 267 47831 157261 110383940
Fatigue 164.99 21.89 172 47926 1215786 109325415
Nephropathy toxic 155.17 21.89 114 47984 27364 110513837
Blood lactate dehydrogenase increased 147.15 21.89 135 47963 44199 110497002
Metastases to lung 144.69 21.89 102 47996 22961 110518240
Rash 142.40 21.89 91 48007 820873 109720328
Nasopharyngitis 139.27 21.89 8 48090 394353 110146848
Abdominal discomfort 139.07 21.89 8 48090 393850 110147351
Salivary gland cancer 137.20 21.89 34 48064 478 110540723
Pyrexia 135.83 21.89 757 47341 897508 109643693
Immune effector cell-associated neurotoxicity syndrome 135.81 21.89 83 48015 14699 110526502
Pain 134.02 21.89 131 47967 954824 109586377
Weight increased 127.86 21.89 16 48082 419628 110121573
Neoplasm recurrence 125.68 21.89 56 48042 5176 110536025
Peripheral swelling 124.08 21.89 15 48083 404019 110137182
Insomnia 122.34 21.89 9 48089 360581 110180620
Product dose omission issue 121.92 21.89 4 48094 321778 110219423
Dizziness 121.55 21.89 77 48021 698116 109843085
Drug hypersensitivity 117.07 21.89 27 48071 454063 110087138
Posterior reversible encephalopathy syndrome 116.06 21.89 105 47993 33756 110507445
Headache 109.43 21.89 134 47964 882243 109658958
Dyspnoea 108.34 21.89 198 47900 1106674 109434527
Osteosarcoma 107.51 21.89 27 48071 402 110540799
Blood stem cell transplant failure 107.27 21.89 30 48068 688 110540513
Fanconi syndrome acquired 104.67 21.89 42 48056 2992 110538209
Pruritus 102.74 21.89 63 48035 581497 109959704
Anal inflammation 101.78 21.89 39 48059 2457 110538744
Wheezing 97.29 21.89 3 48095 255227 110285974
Hypogammaglobulinaemia 97.23 21.89 76 48022 20000 110521201
Swelling 96.38 21.89 18 48080 351023 110190178
Musculoskeletal stiffness 94.85 21.89 7 48091 279815 110261386
Hypersensitivity 92.90 21.89 30 48068 403968 110137233
Urticaria 92.74 21.89 14 48084 318843 110222358
Arthropathy 92.51 21.89 9 48089 287513 110253688
Contraindicated product administered 90.91 21.89 4 48094 248263 110292938
B-cell lymphoma recurrent 89.05 21.89 29 48069 1129 110540072
Contusion 88.03 21.89 3 48095 233358 110307843
Rhabdomyosarcoma recurrent 87.42 21.89 19 48079 143 110541058
SARS-CoV-2 test negative 85.50 21.89 33 48065 2120 110539081
Therapeutic product effect decreased 83.12 21.89 6 48092 244310 110296891
Pain in extremity 82.94 21.89 55 48043 487063 110054138
Malaise 82.17 21.89 103 47995 671716 109869485
Lymphopenia 80.03 21.89 93 48005 40077 110501124
Platelet count decreased 79.89 21.89 251 47847 230192 110311009
Infusion related reaction 79.69 21.89 33 48065 381129 110160072
Metastases to lymph nodes 79.57 21.89 60 48038 14972 110526229
Abdominal pain upper 78.37 21.89 27 48071 349084 110192117
Muscle spasms 74.78 21.89 15 48083 278142 110263059
Pneumothorax 74.19 21.89 84 48014 35201 110506000
Glossodynia 73.97 21.89 6 48092 221998 110319203
Dry mouth 73.94 21.89 3 48095 199945 110341256
Sinusitis 73.77 21.89 19 48079 296669 110244532
Pericarditis 72.79 21.89 6 48092 219108 110322093
Drug ineffective for unapproved indication 71.56 21.89 146 47952 102692 110438509
Metastases to peritoneum 71.55 21.89 39 48059 5571 110535630
Myeloid leukaemia 70.96 21.89 23 48075 882 110540319
Neutrophil count decreased 70.71 21.89 160 47938 120781 110420420
Venoocclusive liver disease 70.27 21.89 56 48042 15151 110526050
T-cell lymphoma refractory 70.09 21.89 15 48083 104 110541097
Impaired healing 69.38 21.89 4 48094 196713 110344488
Inappropriate schedule of product administration 69.27 21.89 5 48093 203632 110337569
Cough 67.31 21.89 61 48037 461580 110079621
Blood pressure increased 65.28 21.89 16 48082 258357 110282844
Injection site pain 64.69 21.89 3 48095 177919 110363282
Premature menopause 63.87 21.89 22 48076 1020 110540181
Musculoskeletal pain 63.70 21.89 4 48094 183019 110358182
Hypertension 63.59 21.89 77 48021 510007 110031194
Mobility decreased 63.41 21.89 13 48085 237409 110303792
Gastrooesophageal reflux disease 62.44 21.89 4 48094 179972 110361229
Tubulointerstitial nephritis 62.32 21.89 96 48002 54188 110487013
Condition aggravated 61.92 21.89 143 47955 734693 109806508
Hypoaesthesia 59.79 21.89 31 48067 314192 110227009
Myalgia 59.75 21.89 12 48086 222369 110318832
Discomfort 58.93 21.89 11 48087 214696 110326505
Ovarian disorder 58.77 21.89 18 48080 572 110540629
Duodenal ulcer perforation 58.65 21.89 5 48093 177695 110363506
Gene mutation 58.56 21.89 29 48069 3400 110537801
Leukoencephalopathy 58.44 21.89 41 48057 9154 110532047
Hepatic enzyme increased 57.67 21.89 34 48064 320858 110220343
Acute lymphocytic leukaemia 57.16 21.89 34 48064 5731 110535470
White blood cell count decreased 57.10 21.89 224 47874 229166 110312035
Polyneuropathy 57.00 21.89 70 48028 31942 110509259
Candida infection 56.66 21.89 86 48012 47923 110493278
Lymphoma 56.60 21.89 56 48042 20115 110521086
Delayed puberty 56.41 21.89 14 48084 198 110541003
Anxiety 56.01 21.89 41 48057 345037 110196164
Depression 55.11 21.89 35 48063 317300 110223901
Staphylococcal infection 54.32 21.89 104 47994 69840 110471361
Subdural hygroma 54.10 21.89 17 48081 589 110540612
Hepatitis B reactivation 53.79 21.89 36 48062 7448 110533753
Ejection fraction decreased 53.68 21.89 77 48021 40803 110500398
Proctalgia 53.35 21.89 45 48053 13177 110528024
Type 2 diabetes mellitus 53.34 21.89 7 48091 177225 110363976
Loss of personal independence in daily activities 53.05 21.89 3 48095 150017 110391184
Bacteraemia 52.98 21.89 78 48020 42312 110498889
Drug resistance 52.91 21.89 91 48007 56283 110484918
Renal impairment 52.68 21.89 191 47907 188254 110352947
Blister 52.03 21.89 17 48081 227359 110313842
Nephrogenic diabetes insipidus 51.87 21.89 24 48074 2421 110538780
Chest pain 49.93 21.89 54 48044 376321 110164880
Recurrent cancer 49.86 21.89 26 48072 3397 110537804
Device related infection 49.80 21.89 73 48025 39446 110501755
Leukoerythroblastosis 49.65 21.89 14 48084 331 110540870
Nervous system disorder 49.57 21.89 65 48033 31656 110509545
Renal tubular injury 49.30 21.89 25 48073 3083 110538118
Venoocclusive disease 49.17 21.89 32 48066 6318 110534883
Pleuroparenchymal fibroelastosis 48.95 21.89 14 48084 349 110540852
Aspergillus infection 48.85 21.89 58 48040 25558 110515643
Oligohydramnios 48.82 21.89 27 48071 3967 110537234
Transformation to acute myeloid leukaemia 48.82 21.89 20 48078 1503 110539698
Systemic candida 48.82 21.89 38 48060 9936 110531265
Clostridium difficile infection 48.72 21.89 84 48014 52045 110489156
Metastases to spleen 48.57 21.89 17 48081 827 110540374
Metastases to muscle 48.14 21.89 14 48084 371 110540830
Encephalitis enteroviral 47.93 21.89 13 48085 265 110540936
Dyspepsia 47.89 21.89 12 48086 190953 110350248
Therapy non-responder 47.89 21.89 164 47934 157143 110384058
Respiratory failure 47.82 21.89 203 47895 215129 110326072
Ganglioneuroblastoma 47.72 21.89 9 48089 29 110541172
Cytomegalovirus infection 47.35 21.89 85 48013 54359 110486842
Diffuse large B-cell lymphoma 46.22 21.89 45 48053 15853 110525348
Agranulocytosis 45.73 21.89 90 48008 61670 110479531
Urinary tract infection 45.32 21.89 45 48053 326237 110214964
Quadriplegia 45.30 21.89 26 48072 4101 110537100
Folliculitis 45.13 21.89 9 48089 167644 110373557
Gastrointestinal toxicity 45.10 21.89 38 48060 11110 110530091
Hospitalisation 44.42 21.89 5 48093 142488 110398713
Azoospermia 44.18 21.89 12 48086 246 110540955
Metastases to breast 44.08 21.89 13 48085 362 110540839
Gait disturbance 43.92 21.89 34 48064 278174 110263027
Ameloblastoma 43.21 21.89 10 48088 103 110541098
Overdose 43.09 21.89 24 48074 233770 110307431
Myelopathy 42.93 21.89 28 48070 5548 110535653
Drug clearance decreased 42.68 21.89 25 48073 4097 110537104
Multiple organ dysfunction syndrome 42.59 21.89 154 47944 151556 110389645
Cardiomyopathy 42.35 21.89 62 48036 33463 110507738
Gait inability 41.98 21.89 5 48093 136371 110404830
Progressive multifocal leukoencephalopathy 41.92 21.89 53 48045 24903 110516298
Metastases to bone marrow 41.90 21.89 16 48082 998 110540203
C-reactive protein abnormal 41.85 21.89 4 48094 129691 110411510
Escherichia bacteraemia 41.85 21.89 35 48063 10129 110531072
Influenza 41.69 21.89 11 48087 169090 110372111
Asthenia 41.39 21.89 157 47941 688842 109852359
Metastases to liver 41.21 21.89 63 48035 35323 110505878
Myocardial infarction 41.15 21.89 16 48082 192067 110349134
Bronchitis 41.09 21.89 9 48089 157023 110384178
Stem cell transplant 41.02 21.89 25 48073 4402 110536799
Vena cava thrombosis 41.02 21.89 23 48075 3471 110537730
Muscular weakness 40.98 21.89 29 48069 248439 110292762
Metastases to meninges 40.09 21.89 26 48072 5102 110536099
Osteosarcoma recurrent 40 21.89 10 48088 146 110541055
Palpitations 39.93 21.89 10 48088 159202 110381999
Neuropathy peripheral 39.79 21.89 169 47929 179108 110362093
Accident 39.58 21.89 35 48063 10917 110530284
Neck pain 39.20 21.89 4 48094 123126 110418075
Hypoalbuminaemia 38.66 21.89 55 48043 28919 110512282
Chromosome analysis abnormal 38.47 21.89 11 48087 274 110540927
Cellulitis gangrenous 38.24 21.89 12 48086 414 110540787
Metastases to retroperitoneum 38.18 21.89 12 48086 416 110540785
Renal failure 38.11 21.89 197 47901 226377 110314824
Haematopoietic stem cell mobilisation 38.04 21.89 12 48086 421 110540780
Arachnoiditis 37.92 21.89 15 48083 1029 110540172
Lymphadenopathy 37.91 21.89 85 48013 63750 110477451
Hyperhidrosis 37.87 21.89 17 48081 187281 110353920
Haemophagocytic lymphohistiocytosis 36.49 21.89 56 48042 31503 110509698
Oedema peripheral 36.46 21.89 54 48044 328606 110212595
Paraesthesia 36.30 21.89 40 48058 276481 110264720
Metastases to central nervous system 36.03 21.89 47 48051 22770 110518431
Hepatitis E 35.83 21.89 23 48075 4436 110536765
Parasitic gastroenteritis 35.44 21.89 10 48088 237 110540964
Rectal haemorrhage 35.42 21.89 5 48093 119828 110421373
Abdominal distension 35.23 21.89 16 48082 175087 110366114
Basal cell naevus syndrome 34.66 21.89 7 48091 35 110541166
BK virus infection 34.23 21.89 35 48063 13071 110528130
Incorrect dose administered 33.97 21.89 3 48095 103638 110437563
Hepatotoxicity 33.89 21.89 81 48017 63319 110477882
Hyperkalaemia 33.16 21.89 9 48089 135787 110405414
Hepatosplenomegaly 33.08 21.89 26 48072 6893 110534308
Metastasis 33.07 21.89 28 48070 8239 110532962
Oedema 32.70 21.89 26 48072 209950 110331251
Dysplasia 32.66 21.89 16 48082 1832 110539369
Pneumonia fungal 32.51 21.89 36 48062 14718 110526483
Electrolyte imbalance 32.44 21.89 58 48040 36970 110504231
Oesophageal candidiasis 32.32 21.89 32 48066 11502 110529699
Diabetes mellitus 32.24 21.89 3 48095 99378 110441823
Bronchopulmonary aspergillosis 31.76 21.89 51 48047 29812 110511389
Deafness 31.73 21.89 48 48050 26661 110514540
Cardiac failure congestive 31.65 21.89 13 48085 150987 110390214
Neutropenic colitis 31.62 21.89 27 48071 8038 110533163
Vulvovaginitis 31.38 21.89 10 48088 363 110540838
Migraine 31.08 21.89 18 48080 171634 110369567
Recall phenomenon 30.54 21.89 14 48084 1382 110539819
Tumour haemorrhage 30.15 21.89 22 48076 5223 110535978
Peripheral blood stem cell apheresis 30.08 21.89 8 48090 151 110541050
Osteonecrosis 29.75 21.89 53 48045 33688 110507513
Myelitis 29.40 21.89 18 48080 3195 110538006
Amniotic fluid index decreased 29.23 21.89 6 48092 33 110541168
Synovial sarcoma 29.19 21.89 7 48091 85 110541116
Feeling hot 28.90 21.89 3 48095 91103 110450098
Rickets 28.75 21.89 7 48091 91 110541110
Rhabdomyosarcoma 28.71 21.89 8 48090 181 110541020
Autoimmune neutropenia 28.60 21.89 11 48087 700 110540501
Meningitis tuberculous 28.54 21.89 13 48085 1265 110539936
Ovarian failure 28.53 21.89 12 48086 964 110540237
Infection 28.42 21.89 261 47837 361939 110179262
General physical health deterioration 28.11 21.89 93 48005 425202 110115999
Adenoviral hepatitis 28.11 21.89 12 48086 1000 110540201
Balance disorder 27.94 21.89 8 48090 116552 110424649
Liver function test increased 27.87 21.89 3 48095 88545 110452656
Salivary gland neoplasm 27.76 21.89 7 48091 106 110541095
Neuroblastoma recurrent 27.75 21.89 10 48088 530 110540671
Adverse drug reaction 27.72 21.89 6 48092 105553 110435648
Enterococcal infection 27.68 21.89 39 48059 20327 110520874
Oxygen saturation decreased 27.67 21.89 17 48081 156965 110384236
Heart rate increased 27.62 21.89 14 48084 143820 110397381
Renal tubular acidosis 27.61 21.89 20 48078 4695 110536506
Inflammation 27.58 21.89 26 48072 193212 110347989
Haematochezia 27.56 21.89 8 48090 115516 110425685
Memory impairment 27.52 21.89 27 48071 196917 110344284
Pseudomonas infection 27.50 21.89 46 48052 27807 110513394
Disorientation 27.29 21.89 80 48018 70591 110470610
Periorbital cellulitis 27.23 21.89 12 48086 1080 110540121
Nasal congestion 27.03 21.89 5 48093 98277 110442924
Hyperbilirubinaemia 26.81 21.89 48 48050 30623 110510578
Acute kidney injury 26.70 21.89 406 47692 635024 109906177
Human herpesvirus 8 infection 26.65 21.89 14 48084 1857 110539344
Pseudomonal bacteraemia 26.64 21.89 19 48079 4352 110536849
Synovial sarcoma metastatic 26.54 21.89 5 48093 16 110541185
Encephalitis cytomegalovirus 26.38 21.89 14 48084 1896 110539305
Acute respiratory distress syndrome 26.34 21.89 66 48032 53132 110488069
Wound infection 26.33 21.89 5 48093 96460 110444741
Drug intolerance 26.11 21.89 90 48008 406422 110134779
Metastases to heart 26.01 21.89 9 48089 423 110540778
Post-acute COVID-19 syndrome 25.95 21.89 13 48085 1562 110539639
Heart rate decreased 25.55 21.89 3 48095 82753 110458448
Klebsiella sepsis 25.19 21.89 18 48080 4135 110537066
Generalised tonic-clonic seizure 25.17 21.89 66 48032 54614 110486587
Angioedema 25.06 21.89 6 48092 98494 110442707
Swelling face 24.75 21.89 5 48093 92316 110448885
Amenorrhoea 24.74 21.89 25 48073 9206 110531995
B-cell lymphoma refractory 24.69 21.89 7 48091 169 110541032
Adenovirus reactivation 24.69 21.89 10 48088 730 110540471
Gastritis haemorrhagic 24.59 21.89 16 48082 3157 110538044
Follicular lymphoma 24.49 21.89 10 48088 745 110540456
Herpes simplex 24.16 21.89 32 48066 15732 110525469
Hypophosphataemia 24.13 21.89 48 48050 33134 110508067
Sarcoma metastatic 23.79 21.89 6 48092 91 110541110
Bradycardia 23.29 21.89 20 48078 155497 110385704
Alopecia 23.26 21.89 81 48017 364672 110176529
Skin turgor decreased 23.24 21.89 10 48088 850 110540351
Postictal state 23.15 21.89 14 48084 2432 110538769
Food protein-induced enterocolitis syndrome 23.08 21.89 5 48093 37 110541164
Rash pruritic 23.02 21.89 7 48091 98062 110443139
Ototoxicity 23.00 21.89 17 48081 4114 110537087
Transdifferentiation of neoplasm 22.98 21.89 6 48092 105 110541096
Feeling abnormal 22.77 21.89 27 48071 180684 110360517
Pulmonary fibrosis 22.69 21.89 8 48090 102034 110439167
Graft versus host disease 22.63 21.89 34 48064 18772 110522429
Pneumonia adenoviral 22.56 21.89 9 48089 631 110540570
Klebsiella infection 22.42 21.89 35 48063 19974 110521227
Drug effective for unapproved indication 22.09 21.89 29 48069 14138 110527063
Congestive cardiomyopathy 22.00 21.89 29 48069 14190 110527011
Cataract 21.95 21.89 4 48094 79481 110461720
Alopecia areata 21.95 21.89 13 48085 2174 110539027
Central nervous system necrosis 21.93 21.89 8 48090 439 110540762

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AA06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Nitrogen mustard analogues
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
CHEBI has role CHEBI:22333 alkylating agent
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:78298 environmental contaminant

Related Drugs by ATC class:

L01AA Nitrogen mustard analogues 8 drugs
bendamustinechlorambucilcyclophosphamidemechlorethaminemelphalanmelphalan flufenamideprednimustinetrofosfamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Testicular Germ Cell Tumor indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Burkitt's lymphoma off-label use 118617000
Small cell carcinoma of lung off-label use 254632001 DOID:5409
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Osteosarcoma of bone off-label use 307576001 DOID:3376
Soft or Connective Tissue Sarcoma off-label use
Progressive Diffuse Large B-Cell Lymphoma off-label use
Invasive Bladder Malignancy off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Fanconi syndrome contraindication 40488004 DOID:1062
Hypokalemia contraindication 43339004
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Kidney excision contraindication 108022006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Polyneuropathies contraindication
CNS Toxicity contraindication
Cancer Chemotherapy Induced Hemorrhagic Cystitis contraindication
Severe Bone Marrow Depression contraindication
Bone Metastases contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.54 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019476 VUID
N0000147596 NUI
D00343 KEGG_DRUG
4019476 VANDF
C0020823 UMLSCUI
CHEBI:5864 CHEBI
CHEMBL1024 ChEMBL_ID
DB01181 DRUGBANK_ID
D007069 MESH_DESCRIPTOR_UI
3690 PUBCHEM_CID
7201 IUPHAR_LIGAND_ID
2865 INN_ID
UM20QQM95Y UNII
5657 RXNORM
44391 MMSL
4867 MMSL
d00257 MMSL
002642 NDDF
108757000 SNOMEDCT_US
386904003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ifosfamide HUMAN PRESCRIPTION DRUG LABEL 1 0143-9530 INJECTION 50 mg INTRAVENOUS ANDA 25 sections
Ifosfamide HUMAN PRESCRIPTION DRUG LABEL 1 0143-9531 INJECTION 50 mg INTRAVENOUS ANDA 25 sections
IFEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-3991 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-3991 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-3993 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
IFEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-3993 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-925 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-925 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-926 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-926 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-927 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-927 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-929 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
IFOSFAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10019-929 INJECTION, POWDER, FOR SOLUTION 3 g INTRAVENOUS NDA 26 sections
Ifosfamide HUMAN PRESCRIPTION DRUG LABEL 1 63323-142 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections